HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.

ABSTRACT: The recent approval of clincially effective immune checkpoint inhibitors illustrates the potential of cancer immunotherapy. A challenging task remains the identification of specific targets guiding immunotherapy. Facilitated by technical advances, the direct identification of physiologically relevant targets is enabled by analyzing the HLA ligandome of cancer cells. Since recent publications demonstrate the immunogenicity of ovarian cancer (OvCa), immunotherapies, including peptide-based cancer vaccines, represent a promising treatment approach. To identify vaccine peptides, we employed a combined strategy of HLA ligandomics in high-grade serous OvCa samples and immunogenicity analysis. Only few proteins were naturally presented as HLA ligands on all samples analyzed, including histone dea

SUBMITTER: Peper JK 

PROVIDER: S-EPMC4910750 | biostudies-literature | 2016 May

REPOSITORIES: biostudies-literature